Login Register Cart 0
Generic placeholder image

Current Reviews in Clinical and Experimental Pharmacology

Editor-in-Chief

ISSN (Print): 2772-4328
ISSN (Online): 2772-4336

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Research Article

Drug-induced Neuropsychiatric Adverse Events Using Post-Marketing Surveillance

Author(s): Tomohito Wakabayashi, Takahiro Nakatsuji, Hiroko Kambara, Iku Niinomi, Saki Oyama, Ayaka Inada, Sayaka Ueno, Mayako Uchida, Kazunori Iwanaga, Tatsuya Iida and Keiko Hosohata*

Volume 17, Issue 2, 2022

Published on: 15 February, 2021

Page: [144 - 148] Pages: 5

DOI: 10.2174/1574884716666210215104540

open access plus

Abstract

Background: Several studies reported that abnormal behavior was noted in pediatric patients receiving several drugs, including neuraminidase inhibitors (NIs). However, the information on drugs associated with abnormal behavior in a real-world setting remains limited. The purpose of this study was to clarify the drugs associated with abnormal behavior using a spontaneous reporting system database.

Methods: We performed a retrospective pharmacovigilance disproportionality analysis using the Japanese Adverse Drug Event Report database. Adverse event reports submitted to the Pharmaceuticals and Medical Devices Agency were analyzed, and the reporting odds ratio at 95% confidence interval were calculated.

Results: A total of 1,144 reports of abnormal behavior were identified. The signals were detected through the association of 4 neuraminidase inhibitors (oseltamivir, zanamivir, laninamivir, and peramivir) with the abnormal behaviour. These signals were stronger for oseltamivir than other neuraminidase inhibitors. The signals were also detected for acetaminophen and montelukast.

Conclusion: Our results should be able to raise physicians’ awareness of drugs associated with abnormal behavior, but further investigation of these medications is warranted.

Keywords: Adverse events, spontaneous reporting system, reporting odds ratio, Japanese Adverse Drug Event Report (JADER) database.

« Previous Next »
Graphical Abstract

[1]
Toovey S, Rayner C, Prinssen E, et al. Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review. Drug Saf 2008; 31(12): 1097-114.
[http://dx.doi.org/10.2165/0002018-200831120-00006] [PMID: 19026027]
[2]
Nakano T, Okumura A, Tanabe T, et al. Safety evaluation of laninamivir octanoate hydrate through analysis of adverse events reported during early post-marketing phase vigilance. Scand J Infect Dis 2013; 45(6): 469-77.
[http://dx.doi.org/10.3109/00365548.2012.763104] [PMID: 23373850]
[3]
Toovey S, Prinssen EP, Rayner CR, et al. Post-marketing assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: an updated review. Adv Ther 2012; 29(10): 826-48.
[http://dx.doi.org/10.1007/s12325-012-0050-8] [PMID: 23054689]
[4]
Yorifuji T, Suzuki E, Tsuda T. Oseltamivir and abnormal behaviors: true or not? Epidemiology 2009; 20(4): 619-21.
[http://dx.doi.org/10.1097/EDE.0b013e3181a3d3f6] [PMID: 19367165]
[5]
Mahé J, de Campaigno EP, Chené AL, Montastruc JL, Despas F, Jolliet P. Pleural adverse drugs reactions and protein kinase inhibitors: Identification of suspicious targets by disproportionality analysis from VigiBase. Br J Clin Pharmacol 2018; 84(10): 2373-83.
[http://dx.doi.org/10.1111/bcp.13693] [PMID: 29943846]
[6]
Mendes D, Alves C, Batel-Marques F. Safety profiles of adalimumab, etanercept and infliximab: a pharmacovigilance study using a measure of disproportionality in a database of spontaneously reported adverse events. J Clin Pharm Ther 2014; 39(3): 307-13.
[http://dx.doi.org/10.1111/jcpt.12148] [PMID: 24635532]
[7]
Kose E. Adverse drug event profile associated with pregabalin among patients with and without cancer: analysis of a spontaneous reporting database. J Clin Pharm Ther 2018; 43(4): 543-9.
[http://dx.doi.org/10.1111/jcpt.12683] [PMID: 29574893]
[8]
Oyama S, Hosohata K, Inada A, et al. Drug-induced tubulointerstitial nephritis in a retrospective study using spontaneous reporting system database. Ther Clin Risk Manag 2018; 14: 1599-604.
[http://dx.doi.org/10.2147/TCRM.S168696] [PMID: 30233195]
[9]
Hosohata K, Inada A, Oyama S, Niinomi I, Wakabayashi T, Iwanaga K. Adverse cutaneous drug reactions associated with old- and new- generation antiepileptic drugs using the japanese pharmacovigilance database. Clin Drug Investig 2019; 39(4): 363-8.
[http://dx.doi.org/10.1007/s40261-019-00754-z] [PMID: 30689189]
[10]
Hosohata K, Inada A, Oyama S, Furushima D, Yamada H, Iwanaga K. Surveillance of drugs that most frequently induce acute kidney injury: A pharmacovigilance approach. J Clin Pharm Ther 2019; 44(1): 49-53.
[http://dx.doi.org/10.1111/jcpt.12748] [PMID: 30014591]
[11]
Inada A, Oyama S, Niinomi I, Wakabayashi T, Iwanaga K, Hosohata K. Association of Stevens-Johnson syndrome and toxic epidermal necrolysis with antiepileptic drugs in pediatric patients: Subgroup analysis based on a Japanese spontaneous database. J Clin Pharm Ther 2019; 44(5): 775-9.
[http://dx.doi.org/10.1111/jcpt.13001] [PMID: 31231846]
[12]
Anzai T, Takahashi K, Watanabe M. Adverse reaction reports of neuroleptic malignant syndrome induced by atypical antipsychotic agents in the japanese adverse drug event report (jader) database. Psychiatry Clin Neurosci 2018.
[PMID: 30375086]
[13]
Urushihara H, Doi Y, Arai M, et al. Oseltamivir prescription and regulatory actions vis-à-vis abnormal behavior risk in Japan: drug utilization study using a nationwide pharmacy database. PLoS One 2011; 6(12)e28483
[http://dx.doi.org/10.1371/journal.pone.0028483] [PMID: 22163021]
[14]
Suzuki M, Masuda Y. Effect of a neuraminidase inhibitor (oseltamivir) on mouse jump-down behavior via stimulation of dopamine receptors. Biomed Res 2008; 29(5): 233-8.
[http://dx.doi.org/10.2220/biomedres.29.233] [PMID: 18997437]
[15]
Fukumoto Y, Okumura A, Hayakawa F, et al. Serum levels of cytokines and EEG findings in children with influenza associated with mild neurological complications. Brain Dev 2007; 29(7): 425-30.
[http://dx.doi.org/10.1016/j.braindev.2006.12.005] [PMID: 17287101]
[16]
Huang YC, Lin TY, Wu SL, Tsao KC. Influenza A-associated central nervous system dysfunction in children presenting as transient visual hallucination. Pediatr Infect Dis J 2003; 22(4): 366-8.
[http://dx.doi.org/10.1097/01.inf.0000059763.79081.9a] [PMID: 12690279]
[17]
Lin CH, Huang YC, Chiu CH, Huang CG, Tsao KC, Lin TY. Neurologic manifestations in children with influenza B virus infection. Pediatr Infect Dis J 2006; 25(11): 1081-3.
[http://dx.doi.org/10.1097/01.inf.0000243194.80616.a9] [PMID: 17072138]
[18]
Fukushima W, Ozasa K, Okumura A, et al. Oseltamivir use and severe abnormal behavior in Japanese children and adolescents with influenza: Is a self-controlled case series study applicable? Vaccine 2017; 35(36): 4817-24.
[http://dx.doi.org/10.1016/j.vaccine.2017.07.007] [PMID: 28818475]
[19]
Stergiakouli E, Thapar A, Davey Smith G. Association of acetaminophen use during pregnancy with behavioral problems in childhood: Evidence against confounding. JAMA Pediatr 2016; 170(10): 964-70.
[http://dx.doi.org/10.1001/jamapediatrics.2016.1775] [PMID: 27533796]
[20]
Ystrom E, Gustavson K, Brandlistuen RE, et al. Prenatal exposure to acetaminophen and risk of adhd. Pediatrics 2017; 140(5): 140.
[http://dx.doi.org/10.1542/peds.2016-3840] [PMID: 29084830]
[21]
Haarman MG, van Hunsel F, de Vries TW. Adverse drug reactions of montelukast in children and adults. Pharmacol Res Perspect 2017; 5(5): 5.
[http://dx.doi.org/10.1002/prp2.341] [PMID: 28971612]
[22]
Leung JS, Johnson DW, Sperou AJ, et al. A systematic review of adverse drug events associated with administration of common asthma medications in children. PLoS One 2017; 12(8)e0182738
[http://dx.doi.org/10.1371/journal.pone.0182738] [PMID: 28793336]
[23]
Erdem SB, Nacaroglu HT, Unsal Karkiner CS, Gunay I, Can D. Side effects of leukotriene receptor antagonists in asthmatic children. Iran J Pediatr 2015; 25(5)e3313
[http://dx.doi.org/10.5812/ijp.3313] [PMID: 26495098]
[24]
Baan EJ, de Smet VA, Hoeve CE, et al. Exploratory study of signals for asthma drugs in children, using the eudravigilance database of spontaneous reports. Drug Saf 2020; 43(1): 7-16.
[http://dx.doi.org/10.1007/s40264-019-00870-x] [PMID: 31617080]
[25]
McCarter GC, Blanchard LB. Similar adverse events from two disparate agents implicate lipid inflammatory mediators for a role in anxiety states. Oxf Med Case Rep 2017; 2017(11)omx060
[http://dx.doi.org/10.1093/omcr/omx060] [PMID: 29218228]
[26]
Amritwar AU, Lowry CA, Brenner LA, et al. Mental health in allergic rhinitis: Depression and suicidal behavior. Curr Treat Options Allergy 2017; 4(1): 71-97.
[http://dx.doi.org/10.1007/s40521-017-0110-z] [PMID: 28966902]
[27]
Neha R, Beulah E, Anusha B, Vasista S, Stephy C, Subeesh V. Vemurafenib induced drug reaction with eosinophilia and systemic symptoms (dress): A disproportionality analysis in faers database. Curr Clin Pharmacol 2020.
[http://dx.doi.org/10.2174/1574884715666200628113508] [PMID: 32598268]
[28]
Franciotta D, Kwan P, Perucca E. Genetic basis for idiosyncratic reactions to antiepileptic drugs. Curr Opin Neurol 2009; 22(2): 144-9.
[http://dx.doi.org/10.1097/WCO.0b013e328328f276] [PMID: 19262378]

Rights & Permissions Print Cite
Article Metrics
31
2
1
1
© 2024 Bentham Science Publishers | Privacy Policy